Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.55 USD
−71.17 M USD
0.00 USD
43.50 M
About Inozyme Pharma, Inc.
Sector
CEO
Douglas A. Treco
Headquarters
Boston
Website
Founded
2015
FIGI
BBG00J7QJMC1
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of INZY is 2.81 USD — it has increased by 4.46% in the past 24 hours. Watch Inozyme Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Inozyme Pharma, Inc. stocks are traded under the ticker INZY.
INZY stock has fallen by −19.25% compared to the previous week, the month change is a −44.90% fall, over the last year Inozyme Pharma, Inc. has showed a −26.82% decrease.
We've gathered analysts' opinions on Inozyme Pharma, Inc. future price: according to them, INZY price has a max estimate of 43.00 USD and a min estimate of 12.00 USD. Watch INZY chart and read a more detailed Inozyme Pharma, Inc. stock forecast: see what analysts think of Inozyme Pharma, Inc. and suggest that you do with its stocks.
INZY reached its all-time high on Aug 24, 2020 with the price of 31.65 USD, and its all-time low was 0.99 USD and was reached on Dec 30, 2022. View more price dynamics on INZY chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
INZY stock is 7.55% volatile and has beta coefficient of 2.56. Track Inozyme Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Inozyme Pharma, Inc. there?
Today Inozyme Pharma, Inc. has the market capitalization of 180.51 M, it has decreased by −13.92% over the last week.
Yes, you can track Inozyme Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
Inozyme Pharma, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
INZY earnings for the last quarter are −0.39 USD per share, whereas the estimation was −0.44 USD resulting in a 10.43% surprise. The estimated earnings for the next quarter are −0.40 USD per share. See more details about Inozyme Pharma, Inc. earnings.
Inozyme Pharma, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
INZY net income for the last quarter is −24.57 M USD, while the quarter before that showed −27.03 M USD of net income which accounts for 9.11% change. Track more Inozyme Pharma, Inc. financial stats to get the full picture.
No, INZY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 59.00 employees. See our rating of the largest employees — is Inozyme Pharma, Inc. on this list?
Like other stocks, INZY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Inozyme Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Inozyme Pharma, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Inozyme Pharma, Inc. stock shows the sell signal. See more of Inozyme Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.